Leerink Partners’ Post

Thoughts on this? >> CEO Noubar Afeyan on how Flagship’s newest fund could shape biotech’s future >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #productmarketing #pharma #pharmaceutical

Navigate the ins and outs of strategic industry partnerships with Adam Hostetler, Director of Business Operations at Cook MyoSite, in this upcoming webinar! Register for free and uncover key strategies and best practices for developing a successful biotech partnership >>> https://hubs.ly/Q02xfyJR0

An rNPV can be an invaluable tool in biotech deal negotiations as it offers a realistic, risk-adjusted assessment of a project's value, facilitating more balanced and strategically sound deal terms. Learn more: https://lnkd.in/e9Ja2nVG

Join Locust Walk’s Andy Meyerson on April 11th for the “Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale” panel at the Doing Life Sciences Deal in 2024 event hosted by Mintz. Gain insights into key considerations, deal trends, strategies for dealing with big pharma, and more. Don't miss out on this valuable discussion!   

Quick post about rNPV as a valuable tool in biotech dealmaking https://lnkd.in/epHn_X5H

We are delighted to announce that Labquality, supported by Merieux Equity Partners with its fund Mérieux Participations 4, has acquired Swedish QAdvis AB, strengthening its regulatory affairs and quality management capabilities in the healthcare technology sector ! 🤝   With their strong foothold in the Swedish market and extensive expertise in medical device software, this acquisition fits with Labquality's international growth strategy and consolidates Labquality's position as an expert service provider in the healthcare technology sector.   Mérieux Participations 4 primarily invests in companies with high organic growth and in buy-and-build platforms, exemplified perfectly by Labquality.   Read the press release here ➡ https://lnkd.in/gWWCsKdH   #Labquality #HealthTech #RegulatoryAffairs #Acquisition #Innovation

Thoughts on this? >> Longevity investors look to add $200M to the table with new growth fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #productmarketing #pharmaceutical #healthcare

Thoughts on this? >> Longevity investors look to add $200M to the table with new growth fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

As development cost and complexity continue to increase, it is more important than ever for biotech to be more intentional with the deployment of the funds they secure. In part two of our biotech funding whitepaper series, we share practical considerations to improve asset development programs across operational strategies, acceleration, regulatory, value-building and partnership aspects. https://ow.ly/uyH350RrYLy